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Abstract T cells detect infected and transformed cells via
antigen presentation by major histocompatibility complex
(MHC) molecules on the cell surface. For T cell stimula-
tion, these MHC molecules present fragments of proteins
that are expressed or taken up by the cell. These fragments
are generated by distinct proteolytic mechanisms for
presentation on MHC class I molecules to cytotoxic CD8+
and on MHC class II molecules to helper CD4+ T cells.
Proteasomes are primarily involved in MHC class I ligand
and lysosomes, in MHC class II ligand generation.
Autophagy delivers cytoplasmic material to lysosomes
and, therefore, contributes to cytoplasmic antigen presenta-
tion by MHC class II molecules. In addition, it has been
recently realized that this process also supports extracellular
antigen processing for MHC class II presentation and cross-
presentation on MHC class I molecules. Although the exact
mechanisms for the regulation of these antigen processing
pathways by autophagy are still unknown, recent studies,
summarized in this review, suggest that they contribute to
immune responses against infections and to maintain
tolerance. Moreover, they are targeted by viruses for
immune escape and could maybe be harnessed for
immunotherapy.
Keywords MHC class I .MHC class II . CD8+ T cell .
CD4+ T cell . Cross-presentation . Herpesvirus . Endocytosis
Introduction
T cells detect infected or transformed cells via antigen
presentation by major histocompatibility complex (MHC)
molecules on the cell surface. Helper CD4+ T cells and
cytotoxic CD8+ T cells are restricted by MHC class I and II
molecules, respectively. These molecules display antigens
in the form of peptides on the cell surface. These peptides
are generated via distinct proteolytic processes and loaded
in different cellular compartments on MHC class I and II
molecules. Some antigen processing for peptide presenta-
tion by MHC molecules is assisted by autophagy.
CD8+ T cells, which rapidly expand during immune
responses and mediate cytotoxicity against infected and
tumor cells, recognize octamer or nonamer peptides on
MHC class I molecules [1]. These peptides are thought to
originate primarily from protein degradation by protea-
somes, large multicatalytic proteases in cytosol and nucleus
[2]. These peptides are then imported into the endoplasmic
reticulum (ER) via the transporter associated with antigen
processing (TAP), and can be further trimmed on their N
terminus via ER aminopeptidases associated with antigen
processing (ERAAPs) [3]. Peptides that fulfill the binding
requirements for the expressed MHC class I molecules, so-
called binding motifs, are then loaded into the peptide
binding groove of these molecules in the MHC class I
loading complex. Upon binding of high-affinity ligands,
MHC class I molecules and their peptide cargo are then
released from the ER to travel to the cell surface for
immune surveillance by CD8+ T cells. This model of
antigen loading onto MHC class I molecules predicts that
proteasome substrates are the main source of MHC class I
ligands. Originally, it was assumed that MHC class I
molecules would, therefore, primarily present cytosolic and
nuclear antigens. However, it was noted that certain cell
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types, primarily professional antigen-presenting cells like
dendritic cells (DCs) are capable to display extracellular
antigens on MHC class I molecules by antigen processing
via cross-presentation [4, 5]. During cross-presentation,
endocytosed antigen is thought to escape into the cytosol
by so far poorly defined mechanisms. Whole proteins or
preprocessed protein fragments might be delivered to the
cytosol, and at least for some antigens, vesicular degradation
by insulin regulated aminopeptidase is required for efficient
cross-presentation [6]. In the cytosol, cross-presented anti-
gens can access the proteasome and follow the MHC class I
antigen processing and presentation pathway. The stage of
endosomal maturation, from which cross-presented antigen
is exported, is heavily debated, and early endosomes as well
as late endosomes, including some that might even fuse with
the ER, have been implicated [7–10]. Thus, different antigen
formulations might be cross-presented from different endo-
somes, but, as we will discuss later, antigen assisted in its
exocytosis by macroautophagy might access one of these
cross-presenting compartments very efficiently.
In contrast to MHC class I molecules, MHC class II
molecules present longer peptides of heterogenic size (≥9
amino acids long) to CD4+ T cells, which orchestrate
humoral and cellular immune responses by virtue of their
cytokine production. MHC class II ligands are primarily
products of lysosomal proteolysis [11] and are loaded with
these in late endosomal compartments, called MHC class II
loading compartment (MIIC). MHC class II molecules reach
these late endosomes with the help of a chaperone called
invariant chain (Ii), which prevents premature peptide
binding of MHC class II molecules in ER and Golgi
apparatus, as well as guides MHC class II molecules via its
cytosolic domain to MIICs. In these vesicles, Ii is degraded
by lysosomal proteolysis, and the remnant peptide occupying
the peptide binding groove, class II-associated invariant
chain peptide, is expelled with the help of the chaperones
H2-M or HLA-DM in mouse and man, respectively. These
chaperones also ensure high-affinity peptide ligand binding
to MHC class II molecules. Thus, MHC class II presented
antigens are in their majority proteins that can gain access to
the MIIC. In the classical paradigm of MHC class II antigen
processing, these were thought to be exclusively extracellular
proteins that reach the MIIC after endocytosis. As discussed
later, it has now been realized that autophagy can permit
cytoplasmic antigen to also access this pathway.
With respect to autophagic pathways that can be
involved in antigen processing for MHC presentation, only
macroautophagy and chaperone-mediated autophagy have
so far been investigated, and we want to briefly introduce
the processes and molecules that have been used by
immunologists to elucidate a role for autophagy in antigen
presentation to T cells. During macroautophagy more than
30 autophagy-related gene (atg) products are involved in
the generation and lysosome fusion of cytosolic double-
membrane surrounded vesicles, called autophagosomes
[12]. The sites of autophagosome generation are character-
ized by the assembly of type III phosphoinositide-3 (PI3)
kinase complexes, incorporating Atg6/Beclin-1. Both rough
ER and the outer nuclear leaflet have been identified as
autophagosome formation sites [13–15], but these vesicles
might also be generated at other places. Two ubiquitin-like
systems are involved in autophagosome formation at these
sites with Atg8 and Atg12 as the ubiquitin-like molecules at
their center [16]. In one ubiquitin-like system Atg12 gets
coupled to Atg5 with the assistance of the E1- and E2-like
enzymes Atg7 and Atg10. The Atg12–Atg5 heterodimer
then associates with Atg16L1 and coats the outer autopha-
gosome membrane. It dissociates from the outer membrane,
once the autophagosome is completed, and has been shown
to direct the conjugation of the other ubiquitin-like molecule
Atg8. Atg8 and its most studied mammalian homologue LC3
are coupled to the lipid phosphatydilethanolamine at the
outer and inner autophagosomal membrane with the help of
the E1- and E2-like enzymes Atg7 and Atg3. While it is
recycled from the outer membrane upon autophagosome
completion, it stays associated with the inner membrane and
is degraded with the autophagosome cargo in lysosomes.
Atg8/LC3 catalyses hemifusion of membranes and might
therefore support the elongation of the autophagosome
membrane [17]. In addition, it is used to recruit autophagic
cargo [18–20]. In addition to its role in autophagosome
formation, Atg6/Beclin-1-containing PI3 kinase complexes
are then once more involved in macroautophagy at the stage
of autophagosome fusion with the lysosome [21–24]. In
addition to macroautophagy, chaperone-mediated autophagy
also imports cytosolic proteins into lysosomes for degrada-
tion [25]. Its substrates carry a KFERQ-like signal sequence,
which targets them for direct transport across the lysosomal
membrane. This transport is assisted by cytosolic and
vesicular chaperones of the heat-shock protein family and
the transmembrane protein LAMP2A. Thus, both macro-
autophagy and chaperone-mediated autophagy deliver cyto-
plasmic constituents to lysosomes for degradation. Since T
cells monitor the proteolytic waste of cells for signs of
infection and transformation, it is maybe not surprising that
they also survey substrates of autophagy. The evidence for
this will be discussed below.
Antigen processing for MHC class II presentation via
autophagy
Endogenous pathway
Different studies have now demonstrated that autophago-
somes can deliver cytosolic and nuclear proteins to MHC
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class II loading compartments (Fig. 1), and this phenomenon
occurs in different cell types: in epithelial cells, in B cells,
but also in dendritic cells as the most professional antigen-
presenting cells. Morphological analysis of MHC class II
compartment have revealed that between 30% and 50% of
MHC class II compartment co-stain with the autophagosome
marker Atg8/LC3 [26]. In parallel, using different model
antigens, for the generation of which proteins were coupled
to Atg8/LC3, our group demonstrated that targeting an
antigen to macroautophagy significantly enhances its pro-
cessing and presentation on MHC class II molecules [26]
and (Gannage et al., unpublished observation). In this
section, we discuss different examples of intracellular
antigens from self, viral, and tumor origin that have been
shown to be processed for MHC class II presentation via
macroautophagy.
Evidence that self-antigens can be delivered to MHC
class II loading compartment via macroautophagy came
first from the analysis of MHC class II bound epitopes. In
human B lymphoblastoid cell lines, mass spectrometrical
analysis of the MHC class II ligandome showed that 20% to
30% of self-class II epitopes are derived from cytosolic and
nuclear proteins. A significant change in the MHC
presented amount of these peptides occurred upon
starvation-induced macroautophagy [27]. This self-antigen
presentation via macroautophagy might be involved in
autoimmune diseases. Along these lines, the group of
Ludger Klein has implicated macroautophagy in the
generation of central tolerance by MHC class II antigen
presentation of self-antigens on thymic epithelial cells
(TECs). Using a model of transplantation of Atg5−/− thymi
into wild-type or TCR transgenic mice, Klein et al.
demonstrated that thymic macroautophagy shapes the
repertoire of CD4+ T cells [28]. Macroautophagy in cortical
TECs seemed to be required for positive selection of certain
T cell receptor specificities, while in medullary TECs, it was
required for negative selection. Without macroautophagy-
dependent negative selection, immunopathology was ob-
served in several tissues including the gut, and the symptoms
could be transferred by T cells. Similarly, Kasai and
colleagues demonstrated by immunofluorescence analysis
the colocalization of Atg8/LC3 with MHC class II loading
compartment in TECs, both in vitro (in cTEC and mTEC cell
lines) and in vivo (in thymic cryosection) [29]. In addition,
Western blot analysis of H2-M vesicles isolated from TECs
lines detected the lipidated form of Atg8/LC3 (LC3-II),
suggesting fusion of autophagosomes with these MHC class
II loading compartments. It is tempting to speculate that
macroautophagy allows intracellular antigens, including
peripheral tissue-derived antigen that are transcribed due to
the expression of the transcription factor autoimmune
regulator element, to be presented onto MHC class II
molecules for central tolerance induction by TECs. However,
this self-antigen presentation might also result in autoimmu-
nity, and Janice Blum’s group has indeed shown that the
autoantigens GAD65 and SMA can be better presented to
CD4+ T cells when chaperone-mediated autophagy is
enhanced [30]. These data suggest that both macroautophagy
and chaperone-mediated autophagy transport self-proteins
for MHC class II presentation to CD4+ T cells during
tolerance induction and possibly also autoimmune disease.
Apart from self-antigens, macroautophagy can also
deliver pathogen-derived antigens to MHC class II loading
compartments. This is exemplified by viral antigens in
Epstein Barr virus (EBV) infected B cells. The pathway has
been implicated in the degradation of two latent EBV
antigens, EBV nuclear antigen 1 (EBNA1) and latent
membrane protein 1 (LMP1). LMP1, which is considered
the major oncogene of EBV, induces macroautophagy [31]
and accumulates upon silencing of the two essential
macroautophagy gene products Atg6/Beclin 1 and Atg7.
Therefore, LMP1 seems to regulate its own clearance by
CD4+ T cell
CD8+ T cell
Lysosome
MVB
Autophagosome
Autophagosome
MIIC
Proteasome MHC 
class I
MHC 
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Fig. 1 Macroautophagy assists
in antigen processing for MHC
class I and II presentation. Cy-
tosolic antigen can be directly
transported to MHC class II
loading compartments (MIIC)
via autophagosomes (lower left).
In addition, it might escape
lysosomal degradation and get
exocytosed from multivesicular
bodies (MVB) for uptake by
bystander cells (right and upper
left). The endocytosed antigen
might get loaded onto MHC
class II molecules or escape to
the cytosol for proteasomal
degradation and presentation on
MHC class I molecules
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macroautophagy, but further studies will have to be
performed to demonstrate if this results in CD4+ T cell
epitope generation from LMP1. For the second latent EBV
antigen that is at least partially turned over by macro-
autophagy, EBNA1, antigen processing for MHC class II
presentation via macroautophagy has been demonstrated
[32, 33]. Leung et al. identified two epitopes from EBNA1
that are processed via endogeneous pathways for MHC
class II presentation by EBV-infected B cells. In line with
previously published results from our group [32], one of
these epitopes is delivered to MHC class II loading
compartments via macroautophagy. Interestingly, prevent-
ing nuclear import of EBNA1 by mutating its nuclear
localization sequence strongly enhanced the presentation of
both this and the other CD4+ T cell epitopes. Both of them
were now delivered to MHC class II loading compartment
via macroautophagy. Thus, cytosolic relocation of EBNA1
resulted in broadening the range of CD4+ T cell epitopes,
displayed on MHC class II molecules after macroautoph-
agy. How the relocation of an antigen from the nucleus to
the cytosol can enhance its endogeneous delivery to MHC
class II compartment by macroautophagy remains unclear.
In contrast to this finding, the study by Riedel et al. [34]
suggested that for endogenous MHC class II presentation of
the cytosolic bacterial antigen neomycin phosphotransfer-
ase II via macroautophagy, the relocation of the antigen to
the nucleus does not affect its antigen recognition. The
differences in these two studies might be related to the
nature and expression level of the antigen itself, allowing
them to form cytosolic malfolded protein pools to different
degrees. In another viral infection, herpes simplex virus
type 1 (HSV-1) induces macroautophagy, but this response
is antagonized by the HSV-1 neurovirulence gene product,
infected cell protein (ICP) 34.5, which interacts with the
essential autophagy protein Atg6/Beclin-1. Interestingly, a
mutant virus unable to bind to the Atg6/Beclin-1 protein
induces a significantly stronger CD4+ T cell response in
infected mice [35]. This might imply an essential role of
macroautophagy-mediated MHC class II presentation
during HSV-1 infection. Indeed, Akiko Iwasaki and
colleagues have recently demonstrated that HSV infection
of mice, lacking macroautophagy in DCs, was compro-
mised in raising virus-specific CD4+ T cell responses [36].
Finally, in macrophages and DCs infected with mycobacte-
rium tuberculosis (Mtb), induction of macroautophagy by
rapamycin, IFN-γ, or starvation significantly enhanced the
processing of immunodominant CD4+ T cell epitopes from
the mycobacterial antigen Ag85B [37]. This mechanism is
an active process, occurring only in live Mtb infection, and
is specifically inhibited by RNA silencing of Atg6/Beclin-1.
In addition, vaccination of mice with rapamycin-pretreated
Mtb-infected DCs significantly improved the efficiency of T
cell responses prior to Mtb challenge. This work described
for the first time how the manipulation of macroautophagy
could improve a vaccine strategy. Thus, in the MHC class II
presentation of individual viral antigens via macroauto-
phagy, a role for this pathway in vivo and even immune
evasion by viral inhibition of macroautophagy has been
demonstrated.
A third group of antigens that might fall prey to
macroautophagy are tumor antigens. The implications of
macroautophagy during tumorigenesis are still unclear.
Among others, macroautophagy has been shown to promote
cell survival of cancer cells, but also in parallel to function as
a tumor suppressor pathway in some models. Nevertheless,
the pathway is active in cancer cells and might generate
tumor-derived CD4+ T cell epitopes. As an example, the
protein encoded by the mucin gene 1 (MUC1) has been
described to be processed by macroautophagy after expres-
sion in DCs [38]. In MUC1-transfected DCs, the processing
of MUC1 for MHC class II presentation was found to be
dependent on macroautophagy. This was documented by
significant inhibition of MUC1-specific CD4+ T cell
proliferation during coculture with antigen-expressing DCs
in the presence of PI3 kinase inhibitors (3-methyladenine or
wortmannin), which compromise autophagosome genera-
tion. In contrast, MUC1-specific CD8+ T cell responses were
unaffected by this pathway. Thus, self-derived, pathogen-
derived, and tumor antigens have now been demonstrated to
follow macroautophagy for MHC class II presentation to
CD4+ T cells. This pathway of immune surveillance should
be harnessed during vaccination and for the development of
novel immunotherapies.
Exogenous pathway
In addition to its role in MHC class II presentation of
cytosolic antigens, macroautophagy has recently been shown
to participate in the processing of exogenous antigens and
their delivery to MHC class II compartment (Fig. 1).
Evidence for this pathway has been gathered primarily in
macrophages and DCs. Indeed, three recent studies have
established a role for macroautophagy in the processing of
phagocytosed antigens for MHC class II presentation by
DCs. Particularly, enhanced antigen processing after DC
activation by pathogen associated molecular patterns, as
recognized by toll-like receptors (TLRs) and NOD-like
receptors (NLRs), was supported by macroautophagy.
The first study by the group of Akiko Iwasaki highlighted
the importance of macroautophagy in DCs for CD4+ T cell
priming in vivo [36]. Interestingly, during HSV infection,
macroautophagy seems to be important not only for the
processing of cytosolic endogeneous antigens and their
delivery to MHC class II compartment, but also for the
processing of exogenous phagocytosed antigens. Using
chimeric mice reconstituted with a hematopoietic system
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deficient for Atg5, the authors could demonstrate a defect in
CD4+ T cell responses in vivo upon HSV infection. In
addition, in these chimeric mice, adoptively transferred
ovalbumin (OVA)-specific CD4+ T cells showed an impair-
ment of proliferation after infection with OVA-expressing
Listeria monocytogenes or OVA-expressing HSV. A role of
macroautophagy for MHC class II antigen processing and
presentation in vivo in professional antigen-presenting cells
was further supported by mice with a conditional deletion of
Atg5 in their DCs. Indeed in these mice, HSV infection
failed to prime CD4+ T cell responses in vivo, and the mice
succumbed to a more severe disease compared with wild-
type mice and developed a higher clinical score upon
infection. In the same study, the authors ruled out a general
defect in macroautophagy-deficient DCs, by demonstrating
that they had no defect in their migration capability, in their
phenotypic maturation (CD86, CD40, and MHC class II
expression), and in their cytokines production, and were not
impaired in endocytosis or phagocytosis compared with
wild-type DCs. Instead, the defect in extracellular antigen
presentation on MHC class II molecules was rather due to an
impairment of processing of phagocytosed antigens that
trigger TLR stimulation. Using lipopolysaccharide-coated
OVA beads, an impairment of phagosome to lysosome
fusion was observed in Atg5−/− DCs, resulting in a reduction
of the processing of phagocytosed antigen for MHC class II
presentation. This phenotype was the consequence of a defect
in the delivery of lysosomal proteases to phagosomes, as well
as a delay of fusion of phagosomes with lysosomes. The
precise mechanism of how the macroautophagy machinery is
recruited to phagosomes and might enhance fusion with
lysosomes remains unclear, but these findings are in line with
previous studies, documenting enhanced antigen presentation
of TLR ligand-coated antigen and Atg-supported fusion of
phagosomes containing such antigen with lysosomes [39, 40].
In one of these studies, the authors described that TLR
engagement induces “LC3-associated phagocytosis” (LAP).
Upon TLR2 stimulation, a recruitment of Atg8/LC3 to the
phagosomal membrane was observed, resulting in an en-
hanced maturation of the phagosome. These studies suggest
that macroautophagy facilitates endocytosed antigen delivery
to lysosomes and MHC class II presentation of this antigen.
Along the same lines, Alison Simmons and colleagues
demonstrated that upon nucleotide-binding oligomerization
domain-containing-2 (NOD2) activation, macroautophagy
is upregulated and involved in MHC class II processing of
phagocytosed antigens [41]. This study provided for the
first time evidence that a defect in macroautophagy
mediated MHC class II antigen presentation could result
in defective CD4+ T cell responses, which might then not
be able to control the gut commensals in Crohn disease
(CD). This defect in macroautophagy-mediated MHC class
II antigen presentation could be caused by mutations in
both the Atg16L1 and NOD2 gene, which had been
identified as major risk factors for the occurrence of the
disease. The authors demonstrated that a bacterial peptido-
glycan muramyl dipeptide (MDP) induces macroautophagy
upon NOD2 activation in human DCs. MHC class II
expression on the cell surface of MDP-activated DCs was
upregulated and this upregulation was dependent on macro-
autophagy. In parallel, a colocalization of Atg8/LC3 with
MHC class II loading compartments was observed. More-
over, DC-mediated priming of CD4+ T lymphocytes after
Salmonella enterica infection was dependent on NOD2 and
Atg16L1 because CD4+ T cell proliferation was compro-
mised by siRNA-mediated silencing of these two genes.
The second part of this study analyzed the function of DCs
from CD patients, carrying either the NOD (3020insC) or
the Atg16L1 (T300A) mutation, which are associated with
the familial form of the disease. In both cases, the cells
demonstrated a defect in macroautophagy upregulation
upon MDP stimulation or S. enterica infection. As a
consequence, MHC class II upregulation and CD4+ T cell
proliferation were compromised. Confirming these find-
ings, the group of Dana Philpott could demonstrate that
NOD1 and 2 stimulation upregulated macroautophagy and
led to autophagosome recruitment to the plasma membrane
[42]. This regulation was independent of the classical
pathway of NLR activation, involving usually the RIP2
adaptor and NF-κB transcription factor. These data suggested
that also NLR-ligand stimulated MHC class II upregulation
and antigen presentation requires macroautophagy.
Finally, a third recent study describes a new mechanism
of immune escape of human immunodeficiency virus (HIV)
1 virus in DCs [43]. In this work, HIV-1 was shown to
inhibit macroautophagy initiation by activating the mTor
pathway. This inhibition resulted in an impairment of TLR4
and TLR8 activation by viral replication intermediates and
of antigen presentation to CD4+ T cells. Indeed, in an in
vitro assay of DC capture of inactivated HIV virus,
macroautophagy was shown to be important for MHC class
II antigen processing of a HIV gag-derived CD4+ T cell
epitope. TNF-α secretion of an HIV gag-specific CD4+ T
cell clone was significantly reduced upon stimulation with
macroautophagy-deficient DCs, pulsed with inactivated
HIV virus. In parallel, CD8+ T cell activation was not
compromised by macroautophagy inhibition. This study
suggests that efficient HIV antigen processing for MHC
class II presentation by DCs requires macroautophagy.
Macroautophagy in antigen processing for MHC class I
presentation
In contrast to a quite robust role for macroautophagy in
MHC class II antigen presentation, much less is known
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about how this pathway influences antigen processing for
MHC class I presentation. Indeed, in several studies, MHC
class I-restricted antigen recognition was actually used as a
control, and no effect of macroautophagy inhibition on
CD8+ T cell recognition was observed [26, 36, 43].
However, under certain circumstances, macroautophagy
might enhance antigen presentation on MHC class I
molecules to CD8+ T cells, and we will summarize the so
far sparse evidence for this here.
The only study so far that argues for a role of macro-
autophagy in endogenous antigen processing for MHC
class I presentation by the group of Michel Desjardins
suggested that late during HSV infection macroautophagy
supports MHC class I presentation of viral antigens [15].
This in vitro finding was restricted to an immunodominant
CD8+ T cell epitope of the glycoprotein B of the virus, and
to its processing during the late stage of the infection.
Interestingly, early after infection (6–8 h), the presentation
of this epitope followed the classical MHC class I pathway,
but later on (8–12 h), macroautophagy inhibition compro-
mised presentation to CD8+ T cells; even so, processing of
this antigen was still dependent on components of the
classical MHC class I antigen processing pathway like the
proteasome and TAP. In infected macrophages, the authors
demonstrated that silencing the essential autophagy gene
atg5 resulted in a decrease of HSV gB-specific CD8+ T cell
recognition. Electron microscopy analysis revealed that the
formation of autophagosomes after HSV-1 infection in-
volved the outer nuclear membrane. However, it was not
clarified by which mechanism autophagosome cargo can
escape to the cytosol to be further processed by protea-
somes. Irrespective of the mechanism, this study suggests
that macroautophagy might intersect with the cross-
presentation pathway of MHC class I antigen processing.
A similar intersection with endosomes capable of cross-
presentation was proposed for macroautophagy substrates
of antigen donor cells (Fig. 1). The first report showing a
direct involvement of macroautophagy in cross-presentation
was by Li and colleagues [44]. In this study, 293T cells
expressing the model antigen OVA in vitro, or melanoma
cells expressing the gp100 melanoma antigen in vivo, were
used as donor cells to access cross-presentation. In both
cases, siRNA-mediated silencing of macroautophagy in
antigen donor cells resulted in a significant reduction of
CD8+ T cell activation after cross-presentation by DCs.
Interestingly, purified autophagosomes from antigen donor
cells were also efficiently cross-presented to CD8+ T cells,
probably acting like exosomes. Therefore, antigen wrapped
in macroautophagic membranes might be more efficiently
taken up by antigen-presenting cells and cross-presented on
MHC class I molecules.
In a second report along these lines by the group of
Matthew Albert [45], evidence was provided that efficient
cross-presentation of viral antigens required macroautoph-
agy in antigen donor cells. In this study, two cellular
sources were used to provide antigen for cross-presentation
experiments, wild-type mouse embryonic fibroblasts
(MEFs) and Bax/Bak−/− MEFs. While wild-type MEFs
can undergo caspase-dependent apoptosis, Bax/Bak−/−
MEFs are unable to perform this type of cell death, but
upregulate macroautophagy under the applied treatment
conditions. Both cell types were infected with influenza A
virus, then treated with proapoptotic agents and adoptively
transferred in vivo for priming experiment. Mice immu-
nized with Bax/Bak−/− MEFs showed a significantly higher
CD8+ T cell response specific to both HA518–526 and NP
366–374 immunodominant CD8
+ T cell epitopes, compared
with mice immunized with wild-type MEFS. These find-
ings again suggest that macroautophagy might package
antigen efficiently for cross-presentation by DCs. How
macroautophagic substrates, however, leave antigen donor
cells for cross-presentation remains to be determined.
Viral evasion from macroautophagy
The important role of macroautophagy during immune
responses is further underscored by its regulation during
viral infections. Three in vivo systems have linked macro-
autophagy to immune control of viral infections. These
included with HSV one DNA, and with Sindbis virus and
vesicular stomatitis virus (VSV) two RNA virus. Neuro-
virulence of both HSV and Sindbis virus was attenuated
when macroautophagy was elevated either by mutation of
the macroautophagy inhibiting ICP34.5 HSV gene product
[46], or by overexpression of Atg6/Beclin-1, driving macro-
autophagy, in Sindbis virus-infected mice [47]. Furthermore,
Sindbis virus infection of the CNS is augmented by
macroautophagy inhibition via either recombinant viruses
encoding a dominant negative Atg5 protein, recombinant
viruses deleting floxed Atg5 upon infection via cre-
recombinase expression or wild-type virus infection of mice
with conditional Atg5 deletion in neurons [48]. In addition,
VSV infection induced macroautophagy in Drosophila flies
and restricted VSV infection in this model organism [49].
These studies did not implicate antigen processing for MHC
presentation via macroautophagy in the protection from virus
infection. However, during HSV infection, macroautophagy
in myeloid DCs was found to be required for efficient
priming of protective CD4+ T cell responses [36]. These
studies implicate that macroautophagy restricts viral replica-
tion in vivo.
Another indication that macroautophagy significantly
limits viral replication is that successful viral pathogens
have developed immune escape mechanisms to target this
pathway. In this respect, two checkpoints of macroautophagy
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are inhibited by viruses. These are autophagosome formation
and autophagosome fusion with lysosomes. Interestingly,
DNA viruses seem to primarily compromise autophagosome
formation, while RNA viruses block autophagic cargo
degradation in lysosomes. With respect to the inhibition of
autophagosome formation, herpesviruses have proven a rich
source of macroautophagy inhibiting proteins. Within the
α-herpesviruses, HSV encodes the late ICP34.5, which
blocks autophagosome formation [50, 51]. ICP34.5 inhibits
autophagosome generation by binding to Atg6/Beclin-1 [46].
Interestingly, HSV with a mutant ICP34.5 protein, lacking
the Atg6/Beclin-1 interacting domain, shows increased
neurovirulence after CNS injection in mice [46]. Within the
β-herpesviruses, human cytomegalovirus also inhibits
macroautophagy [52]. However, the molecular mechanism
of this regulation is unknown so far. Finally, the group of
γ-herpesviruses contains several members that compromise
autophagosome formation, namely Kaposi sarcoma associ-
ated herpesvirus (KSHV) and murine γ-herpesvirus (MHV-
68). KSHV encodes a B cell lymphoma 2 protein (Bcl-2)
homologue, encoded by ORF-16 of the virus, which also
interacts with Atg6/Beclin-1 and inhibits autophagosome
formation [53]. In addition, the same virus compromises
autophagosome formation also via its viral FLICE inhibitory
protein (v-FLIP) protein, encoded by ORF71/K13 [54].
KSHV v-FLIP impairs Atg3, the E2-like enzyme of Atg8/
LC3 lipidation. This mechanism prevents Atg8/LC3-
dependent autophagosome formation. Therefore, KSHV
expresses with v-FLIP a macroautophagy inhibitor during
latent, and with v-Bcl-2 one during lytic infection. The
closest rodent virus to KSHV, MHV-68, also expresses a
Bcl-2 homologue, M11, which interacts with Atg6/Beclin-1
to inhibit autophagosome formation [55]. Deletion of the
macroautophagy blocking, but not the apoptosis compromis-
ing domain, impairs the establishment of chronic infection by
this virus [56]. Collectively, these data suggest that herpesvi-
ruses inhibit autophagosome formation in order to inhibit
restriction of viral infection and viral antigen presentation.
In addition to autophagosome generation as a first
checkpoint of macroautophagy, degradation of these vesicles
via fusion with lysosomes is targeted by RNA viruses.
Already, early electron microscopy studies of poliovirus-
infected cells reported the accumulation of double-membrane
engulfed vesicles [57]. This stabilization of autophagosomes
could be induced by the viral proteins 2BC and 3A [58],
even so the molecular mechanism underlying this presumed
block in autophagosome degradation remains unclear.
Formation of these poliovirus stabilized vesicles is dependent
on some Atg proteins because siRNA-mediated silencing of
Atg8/LC3 and Atg12 inhibits their generation, and they seem
to represent, therefore, a subtype of autophagosomes [58].
The stabilized membranes support viral replication and are
thought to function as a scaffold for viral replication. In
addition, inhibition of autophagosome degradation might
enhance virus particle exocytosis [58]. Furthermore, the
stabilization of autophagosome membranes for viral replica-
tion has been proposed for other RNA viruses, like the
flaviviruses hepatitis C virus (HCV) and dengue virus [59–
63]. Moreover, even RNA viruses that do not use autopha-
gosomal membranes for their replication seem to benefit
from inhibition of autophagosome degradation for their
release of infectious viruses from infected cells [64]. Along
these lines, the HIV was found to block autophagosome
maturation. Particularly, its Nef protein interacts with Atg6/
Beclin-1 blocking degradation of macroautophagic cargo,
including HIV particles. These, therefore, are exocytosed at
increased rates. This benefit for HIV in blocking autophago-
some degradation was only observed in macrophages, but
not T cells. Similarly, a slight benefit of macroautophagy
regulation for the replication of the segmented RNA virus
influenza virus was observed only in canine kidney epithelial
cells, but not in human lung epithelia or mouse embryonic
fibroblasts [65, 66]. Irrespective of a benefit for viral
replication, influenza infection leads to autophagosome
accumulation in a broad range of cell types [66]. The virus
achieves this by blocking autophagosome fusion with
lysosomes via its matrix protein 2. This macroautophagy
block enhances apoptotic cell death of infected cells and
might regulate immunogenic viral protein release. Taken
together, these studies suggest that viruses highjack macro-
autophagy to prevent their degradation and viral antigen
presentation, or even use autophagic membranes for their
own replication and exit from infected cells. Depending on
the need of the virus, they block autophagosome generation
or degradation with DNA viruses targeting preferentially the
first, and RNA viruses the second checkpoint of macro-
autophagy, respectively.
Conclusions
Macroautophagy supports adaptive immune responses by
facilitating antigen processing for MHC presentation to T
cells. Since autophagosomes direct cytoplasmic content for
lysosomal degradation and MHC class II molecules present
lysosomal products to CD4+ T cells, most studies suggest a
role for macroautophagy in antigen presentation to these
helper T cells. However, some studies also describe that
macroautophagy might even assist MHC class I antigen
presentation to CD8+ T cells. While intracellular antigen
presentation by MHC class II molecules seems to benefit
from macroautophagic substrate delivery to MHC class II
loading compartments, the mechanisms by which extracel-
lular antigen delivery to these MIICs is supported by
macroautophagy, by which autophagosome content can
again escape to the cytosol for classical MHC class I antigen
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presentation, and by which antigen can be efficiently
packaged by macroautophagy for cross-presentation remain
unclear. The evidence that viruses, however, target this
pathway for their immune escape suggests that it might be
important for immune control. Thus, macroautophagy should
be harnessed to enhance immunotherapies and assist antigen
processing during vaccinations.
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